# What binding-protein measurements tell us about semaglutide

- Article ID: research-332
- Product: SEMA / IGF-1 LR3 (sema-igf-1-lr3-708, sema-igf-1-lr3-709)
- Canonical page: https://heritagebiolabs.com/research-library/articles/332-what-binding-protein-measurements-tell-us-about-semaglutide
- Product collection: https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-708
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-709
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1992, 2025

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short amino-acid chains connected by peptide bonds are peptides. They can signal through receptors or interact with other proteins. Semaglutide activates the GLP-1 receptor. IGF-1 LR3 is a modified insulin-like growth factor protein with altered binding properties. An older human study measured IGF-binding proteins during semaglutide treatment. It helps explain the difference between measuring a change in the body’s growth-factor system and administering a growth-factor analog. [1, 2]

The investigators followed 34 people with type 2 diabetes who were already receiving metformin. Some received semaglutide and some received sitagliptin. The study also included a matched comparison group. Researchers measured several binding proteins over a year. They reported an increase in IGFBP-1 during treatment with either drug. The measured level of another related protein, IGFBP-rp1, did not change significantly with either treatment. These measurements concern proteins already circulating in the participants. [1]

Binding proteins can affect how much IGF-1 is available to receptors. Older cell research describes IGF-1 LR3 as having lower affinity for IGF-binding proteins than ordinary IGF-1. These two observations answer separate questions. One concerns changes in the concentration of proteins in the blood during semaglutide treatment. The other concerns how a modified growth-factor molecule interacts with such proteins in laboratory research. [1, 2]

The one-year study did not administer IGF-1 LR3 or measure the outcome of using it with semaglutide. It therefore cannot tell us whether that combination would change growth-factor signaling, body composition or adverse events. The available study is evidence about blood measurements during treatment with the medications it actually examined. [1, 2]

## Sources

1. E. Dániel et al. Long-Term Effects of Semaglutide and Sitagliptin on Circulating IGFBP-1, IGFBP-3 and IGFBP-rp1: Results from a One-Year Study in Type 2 Diabetes. International Journal of Molecular Sciences (publication 2025-10-26). <https://pubmed.ncbi.nlm.nih.gov/41226444/>
2. R. W. Grimes and J. M. Hammond. Insulin and insulin-like growth factors (IGFs) stimulate production of IGF-binding proteins by ovarian granulosa cells. Endocrinology (publication 1992-08). <https://pubmed.ncbi.nlm.nih.gov/1379161/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 067 - SEMA IGF-1 LR3 and Semax.docx; article 332; content SHA-256 8dfa403a1742b518cfc48c3731dcbcc082aa0712b93d6739b3a28fb5d966c5fa.
